{
    "clinical_study": {
        "@rank": "9859", 
        "acronym": "GES", 
        "arm_group": {
            "arm_group_label": "Gastric Electrical Stimulation (GES)", 
            "arm_group_type": "Experimental", 
            "description": "Gastric Electrical Stimulation (GES) therapy for the treatment of obesity."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this feasibility study is to provide safety data on the implantable Exilis\n      gastric electrical stimulation (GES) system, to individually adjust stimulation parameters\n      to levels that are comfortable for implanted subjects during chronic daily treatment, and to\n      collect data on acute gastrointestinal function and food intake responses to GES during\n      in-clinic testing."
        }, 
        "brief_title": "Gastric Electrical Stimulation (GES) for the Treatment of Obesity", 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults ages 21-64 with BMI of 40-45 kg/m^2 or BMI 35-39.9 kg/m^2 with at least one\n             obesity-related comorbidity, who have failed prior non-surgical weight loss attempts,\n             and have been within 5% of their current weight for at least one year.\n\n          -  If diabetic, subject has non-insulin-dependent type 2 diabetes mellitus diagnosed\n             within the last 7 years, and has an HbA1c level less than 8%.\n\n          -  If female and of child-bearing age, subject is not pregnant or lactating and is\n             willing to use effective contraception for the duration of the study.\n\n          -  Subject is willing and able to complete scheduled study visits, complete on-line\n             lifestyle educational modules, and complete required procedures.\n\n        Exclusion Criteria:\n\n          -  Subject has a history of medical, surgical, or psychiatric conditions that, in the\n             opinion of the Investigators, would limit study participation or contraindicate\n             implantation of the Exilis GES system. Examples includes cardiac abnormalities\n             contraindicating surgical anesthesia, prior gastrointestinal surgery,\n             gastrointestinal motility disorders, inflammatory bowel disease, a history of eating\n             disorders, anticipated future need for magnetic resonance imaging, or allergies to\n             food ingredients in study test meals."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823705", 
            "org_study_id": "Exilis-1"
        }, 
        "intervention": {
            "arm_group_label": "Gastric Electrical Stimulation (GES)", 
            "intervention_name": "Exilis Implantable Gastric Electrical Stimulation (GES)", 
            "intervention_type": "Device", 
            "other_name": "Exilis Implantable Gastric Electrical Stimulation"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 20, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6229"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Gastric Electrical Stimulation (GES) for the Treatment of Obesity", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "Netherlands: Ministry of Health, Welfare and Sport"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percent of subjects experiencing device-related serious adverse events (i.e., events requiring additional medical treatment).", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "The level of gastrointestinal sensations, as rated on a 6-point ordinal scale during in-clinic testing, that corresponds to stimulation settings comfortable for chronic treatment.", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823705"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in gastric emptying time across a pair of in-clinic measurements made with and without GES.", 
                "safety_issue": "No", 
                "time_frame": "8 and 10 weeks"
            }, 
            {
                "measure": "Change in caloric intake across a pair of standardized meals consumed in-clinic with and without GES.", 
                "safety_issue": "No", 
                "time_frame": "8 and 10 weeks"
            }, 
            {
                "measure": "Change in body weight during chronic daily GES treatment.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 months"
            }
        ], 
        "source": "Medtronic Corporate Technologies and New Ventures", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medtronic Corporate Technologies and New Ventures", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}